Mirtazapine is associated with less anxiolytic use among elderly depressed patients in long-term care facilities

Journal of the American Medical Directors Association

Volumn 5, Issue 2, 2004, Pages 101-106

  Gardner, Marie E ^a   Malone, Daniel C ^a   Sey, Mark ^b   Babington, Maude A ^c  

^a UNIVERSITY OF ARIZONA   (United States)

^b Mark Sey and Associates   (United States)

^c Babington Consulting   (United States)

Author keywords

Anxiolytic; Depression; Mirtazapine

Indexed keywords

ALPRAZOLAM; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; APPETITE STIMULANT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CHOLINESTERASE INHIBITOR; CITALOPRAM; CLONAZEPAM; FLUOXETINE; FLURAZEPAM; HYPNOTIC AGENT; LORAZEPAM; MIRTAZAPINE; NEFAZODONE; NEUROLEPTIC AGENT; OXAZEPAM; PAROXETINE; PSYCHOTROPIC AGENT; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TEMAZEPAM; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; ZALEPLON; ZOLPIDEM;

AGE; AGED; ARTICLE; BIPOLAR DEPRESSION; BODY MASS; BODY WEIGHT; CONSULTATION; CONTROLLED STUDY; DATA ANALYSIS; DEPRESSION; DRUG COST; DRUG USE; ELDERLY CARE; FEMALE; GEOGRAPHY; GERIATRIC PATIENT; HEALTH CARE FACILITY; HUMAN; LONG TERM CARE; MAJOR DEPRESSION; MALE; MEDICAL RECORD; NURSING; PHARMACIST; PSYCHIATRIC DIAGNOSIS; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; UNITED STATES;

EID: 1642363282     PISSN: 15258610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-8610(04)70063-8     Document Type: Article

References (28)

1. Mulsant BH, Ganguli M. Epidemiology and diagnosis of depression in late life. J Clin Psychiatry 1999;60(suppl 20):9-15.
2. Brown MN, Lapane KL, Luisi AF. The management of depression in older nursing home residents. J Am Geriatr Soc 2002;50:69-76.
3. Evers MM, Samuels SC, Lantz M, et al. The prevalence, diagnosis and treatment of depression in dementia patients in chronic care facilities in the last six months of life. Int J Geriatr Psychiatry 2002;17:464-472.
4. Doraiswamy PM. Contemporary management of comorbid anxiety and depression in geriatric patients. J Clin Psychiatry 2001;62(suppl 12):30-35.
5. Flint AJ. Anxiety disorders in late life. Can Fam Physician 1999;45: 2672-2679.
6. Schneider LS. Overview of generalized anxiety disorder in the elderly. J Clin Psychiatry 1996;57(suppl 7):34-45.
7. Tariot PN. Treatment strategies for agitation and psychosis in dementia. J Clin Psychiatry 1996;57(suppl 14):21-29.
8. Mintzer JE, Brawman-Mintzer O. Agitation as a possible expression of generalized anxiety disorder in demented elderly patients: Toward a treatment approach. J Clin Psychiatry 1996;57(suppl 7):55-63.
9. Hoyberg OJ, Maragakis BK, Mullin J, et al. A double blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients. Acta Psychiatr Scand 1996;93:184-190.
10. Guelfi JD, Ansseau M, Timmerman L, et al. Mirtazapine versus ventafaxine in hospitalized severely depressed patients with melancholic features. J Clin Psychopharmacol 2001;21:425-431.
11. Fawcett J, Barkin RL. Review of the results from clinical studies on the efficacy, safety and tolerability or mirtazapine for the treatment of patients with major depression. J Affect Disord 1998;51:276-285.
12. Leinonen E, Skarstein J, Behnke K, et al. Efficacy and tolerability of mirtazapine versus citalopram: A double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group. Int Clin Psychopharmacol 1999;14:329-337.
13. Thompson C. Mirtazapine versus selective serotonin reuptake inhibitors. J Clin Psychiatry 1999;60(suppl 17):18-22.
14. Fawcett J, Barkin RL. A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety. J Clin Psychiatry 1998;59: 123-127.
15. Benkert O, Szegedi A, Kohnen R. Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry 2000;61:656-663.
16. deBoer T. The pharmacologic profile of mirtazapine. J Clin Psychiatry 1996;57(suppl 4):19-25.
17. Tobias DE, Sey M. General and psychotherapeutic medication use in 328 nursing facilities: A year 2000 national survey. Consult Pharm 2001;16: 54-64.
18. Gurwitz JH, Field TS, Avorn J, et al. Incidence and preventability of adverse drug events in nursing homes. Am J Med 2000;109:87-94.
19. Sgadari A, LaPane KL, Mor V, et al. Oxidative and nonoxidative benzodiazepines and the risk of femur fracture. J Clin Psychopharmacol 2000;20:234-239.
20. Salzman C, Fisher J, Nobel K, et al. Cognitive improvement following benzodiazepines discontinuation in elderly nursing home residents. Int J Geriatr Psychiatry 1992;7:89-93.
21. Paterniti S, Dufouil C, Alperovitch A. Long-term benzodiazepine use and cognitive decline in the elderly: The Epidemiology of Vascular Aging Study. J Clin Psychopharmacol 2002;22:285-293.
22. Tollefson GD, Holman SL, Sayler ME, et al. Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features. J Clin Psychiatry 1994;55:50-59.
23. Boerner RJ, Moller HJ. The importance of new antidepressants in the treatment of anxiety/depressive disorders. Pharmacopsychiatry 1999;32: 119-126.
24. Feighner JP. Overview of antidepressants currently used to treat anxiety disorders. J Clin Psychiatry 1999;60(suppl 22):18-22.
25. Nutt DJ. Care of depressed patients with anxiety symptoms. J Clin Psychiatry 1999;60(suppl 17):23-27.
26. Katz IR, Reynolds CF III, Alexopoulos GS, et al. Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: Pooled analysis of five randomized placebo-controlled clinical trials. J Am Geriatr Soc 2002;50:18-25.
27. Shatzberg AF, Kremer C, Rodrigues HE, et al. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry 2002;10:541-550.
28. Fava M. Weight gain and antidepressants. J Clin Psychiatry 2000; 61(suppl 11):37-41.